跳到主要內容

臺灣博碩士論文加值系統

(18.205.192.201) 您好!臺灣時間:2021/08/06 05:43
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:林如璠
研究生(外文):Ju-Fan Lin
論文名稱:PTPγ在台灣女性乳癌的高度表現
論文名稱(外文):Overexpression of protein tyrosine phosphatase gamma in Taiwanese women with breast cancers
指導教授:周寬基周寬基引用關係
指導教授(外文):Kuan-Chih Chow
學位類別:碩士
校院名稱:國立中興大學
系所名稱:生物醫學研究所
學門:生命科學學門
學類:生物化學學類
論文種類:學術論文
論文出版年:2008
畢業學年度:96
語文別:中文
論文頁數:85
中文關鍵詞:乳癌丙型蛋白質酪胺酸磷酸酶
外文關鍵詞:breast cancerPTPgamma
相關次數:
  • 被引用被引用:1
  • 點閱點閱:100
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
近二、三十年來,台灣地區乳癌的發生率及死亡率節節上升,已成為女性最好發的癌症。流行病學研究顯示台灣女性乳癌的發生呈現出與歐美國家不同的面貌,其發病年齡呈現年輕化,較歐美國家平均提早了8到10年。然而,目前對於造成此一差異的分子機制仍未完全明瞭。
丙型蛋白質酪胺酸磷酸酶 (protein tyrosine phosphatase gamma, PTPγ)位於第三對染色體短臂14.2的位置,其被推測可能為一腫瘤抑制基因,但卻在淋巴癌及星狀細胞瘤有高度表現的情形。在本研究中,藉由RT-PCR、原位雜交 (in situ hybridization, ISH)及西方墨漬法 (western blot)等技術,我們發現PTPγ在乳癌細胞株及台灣女性乳癌組織檢體都有高度表現的情形。此外,我們也沒有在細胞株及臨床檢體中發現任何特殊的ptprg基因缺失 (deletion)及突變 (mutation)。免疫組織染色結果顯示PTPγ主要分布於腫瘤組織,且令人意外地,有約30%的病患其PTPγ有進到細胞核內的情形。進一步地,我們發現幾乎所有的浸潤性腺管癌 (infiltrating ductal carcinoma, IDC) 的病患,雖其細胞分化程度較差,但都有PTPγ的高度表現;而這樣的情形卻只在58%的浸潤性小葉癌 (infiltrating lobular carcinoma, ILC)病患見到。綜合上述結果,我們證實了PTPγ在台灣女性乳癌的確有高度表現,其可能扮演致癌基因的角色,並可能為一乳癌預後因子及潛在的治療標的。
Breast cancer is a leading cause of cancers in Taiwanese women. The incidence and mortality rate increased rapidly in the past two decades. The average onset age of breast cancer in Taiwan is 8-10 years younger than that in Euro-America. However, the molecular difference is still unclear.
Protein tyrosine phosphatase gamma (PTPγ) is located at chromosome 3p14.2. This molecule is suggested as a tumor suppressor candidate, but is up-regulated during lymphoma and astrocytoma tumorigenesis. In this study, we found that PTPγ was overexpressed in breast cancer cell lines and breast cancer specimens by using RT-PCR, in situ hybridization, and western blot analysis. However, no specific deletion or mutation was found in PTPγ of cancer cell lines or clinical samples. Immunohistochemical staining showed that PTPγ was mainly distributed in tumor lesion, and surprisingly, PTPγ was located in the nucleus in about 30% of tumor samples. Moreover, we found that nearly all infiltrating ductal carcinoma (IDC), but only 58% infiltrating lobular carcinoma (ILC) patients had high level of PTPγ expression. These data indicated that PTPγ is a potential oncogene and may be a prognostic factor and therapeutic target of breast cancer in Taiwan.
中文摘要 Ⅰ
英文摘要 Ⅱ
目次 Ⅲ
表目次 Ⅶ
圖目次 Ⅷ
縮寫字對照表 Ⅸ
第一章 緒論 1
一、乳癌 (breast cancer) 1
1. 乳癌於全球發生之概況 1
2. 乳癌於台灣發生之現況 2
3. 乳癌發生的機轉 3
4. 乳癌的定義與分類 4
5. 乳癌的診斷、治療及預防 5
二、蛋白質酪胺酸磷酸酶超級家族 6
三、丙型蛋白質酪胺酸磷酸酶 10
第二章 研究動機 14
第三章 材料與方法 15
一、材料 15
1. 細胞株 (cell lines) 15
2. 乳癌病人組織檢體 15
3. 引子 (primer)與探針 (probe)之設計 15
4. 質體 (plasmid) 15
5. 勝任細胞 (competent cell) 16
6. 藥品 16
7. 緩衝溶液 16
8. 抗體 16
9. 儀器 16
二、方法 17
1. 細胞培養 (cell culture) 17
(一) 解凍細胞 17
(二) 細胞繼代 (cell passage) 17
(三) 細胞計數 17
2. RNA萃取及反轉錄聚合酶鏈反應 (RT-PCR) 18
(一) 萃取細胞株及乳癌組織檢體之RNA 18
(二) 反轉錄聚合酶鏈反應 (RT-PCR) 18
(三) 瓊脂凝膠電泳 (agarose gel electrophoresis) 19
3. 基因組DNA萃取(genomic DNA extraction)與聚合酶鏈反應 19
(一) 萃取細胞株及乳癌組織檢體之基因組DNA 19
(二) 聚合酶鏈反應 (PCR) 20
(三) 瓊脂凝膠電泳 (agarose gel electrophoresis) 20
4. 細胞與組織切片染色 20
(一) 細胞免疫化學染色法 (immunocytochemistry) 20
(二) 免疫組織化學染色法 (immunohistochemistry, IHC) 21
(三) 原位雜交 (in situ hybridization, ISH) 22
(四) 免疫螢光染色 (immunofluorescence staining) 22
5. 重組質體的構築與增殖 23
(一) 限制酵素切割 (restriction enzyme digestion) 23
(二) 增幅之基因片段與載體之接合 (ligation) 23
(三) 轉型作用 (transformation) 23
6. 重組蛋白之表現 24
(一) 轉型作用 (transformation) 24
(二) 小量製備重組蛋白 24
(三) 大量製備重組蛋白 25
(四) SDS聚丙烯醯胺凝膠電泳 (SDS-PAGE) 25
(五) 轉印與西方墨漬法 (transfer and western blot) 26
7. 蛋白質萃取及蛋白質定量分析 26
(一) 由細胞株及乳癌組織檢體萃取蛋白質 26
(二) 蛋白質定量分析 (protein quantification) 27
8. 多株抗體之製備 (polyclonal antibody production) 27
(一) 小鼠免疫反應 (immunizing mouse) 27
(二) 酵素結合免疫吸附反應 (ELISA) 28
9. pCR II-TOPO 重組質體之製備 28
10. 軟體 29
第四章 實驗結果 30
一、乳癌細胞株及台灣女性乳癌檢體中PTPγ基因表現情形 30
二、PTPγ 細胞膜外區域的基因突變 30
三、乳癌細胞株與台灣女性乳癌檢體PTPγ第14表現子缺失之偵測 32
四、PTPγ原核表現質體之構築及重組蛋白製備 32
五、PTPγ多株抗體之製備 34
六、乳癌細胞株及台灣女性乳癌檢體PTPγ蛋白之表現情形 34
第五章 討論 36
第六章 結論 41
表 42
圖 51
參考文獻 69
附錄 86
行政院衛生署。2006。死因統計。台北。中華民國。

行政院衛生署。2006。衛生統計系列(三)-公務統計。台北。中華民國。

師維孝。2006。發展以電化學偵測Zeranol及分析動情素相關基因於台灣地區女性乳癌之表現,碩士論文。中興大學獸醫學研究所。台中。中華民國。

國家衛生研究院 (NHRI) / 台灣癌症臨床研究合作組織 (TCOG)。2003。乳癌診斷與治療共識。竹南。中華民國。

Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T. 2004. Protein tyrosine phosphatases in the human genome. Cell 117: 699-711.

Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Møller NP. 2001. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell Biol. 21: 7117-7136.

Ardini E, Agresti R, Tagliabue E, Greco M, Aiello P, Yang LT, Ménard S, Sap J. 2000. Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene 19: 4979-4987.
Barnea G, Silvennoinen O, Shaanan B, Honegger AM, Canoll PD, D’Eustachio P, Morse B, Levy JB, Laforgia S, Huebner K. 1993. Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. Mol. Cell Biol. 13: 1497-1506.

Beltran PJ, Bixby JL. 2003. Receptor protein tyrosine phosphatases as mediators of cellular adhesion. Front Biosci. 8: D87-D99.

Bentires-Alj M, Neel BG. 2007. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67: 2420-2424.

Bilwes AM, den Hertog J, Hunter T, Noel JP. 1996. Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Nature 382: 555-559.

Bingham S, Riboli E. 2004. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat. Rev. Cancer 4: 206-215.

Bjorge JD, Pang A, Fujita DJ. 2000. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem. 275: 41439-41446.

Blume-Jensen P, Hunter T. 2001. Oncogenic kinase ignaling. Nature 411: 355-365.

Brennan M, Wilcken N, French J, Ung O, Boyages J. 2005. Management of early breast cancer—the current approach. Aust. Fam. Physician. 34: 755-760.

Buist A, Zhang YL, Keng YF, Wu L, Zhang ZY, den Hertog J. 1999. Restoration of potent protein-tyrosine phosphatase activity into the membrane-distal domain of receptor protein-tyrosine phosphatase alpha. Biochemistry 38: 914-922.

Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. 2002. Cancer epidemiology and control in Taiwan: a brief review. Jpn. J. Clin. Oncol. 32: S66-S81.

Cheng SH, Tsou MH, Liu MC, Jian JJ, Cheng JC, Leu SY, Hsieh CY, Huang AT. 2000. Unique features of breast cancer in Taiwan. Breast Cancer Res. Treat. 63: 213-223.

Cheung KL. 2007. Endocrine therapy for breast cancer: an overview. Breast 16: 327-343.

Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. 2004. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103: 4630-4635.

Dinh P, de Azambuja E, Piccart-Gebhart MJ. 2007. Trastuzumab for early breast cancer: current status and future directions. Clin. Adv. Hematol. Oncol. 5: 707-717.

Dian D, Herold H, Mylonas I, Scholz C, Janni W, Sommer H, Friese K. 2008. Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch. Gynecol. Obstet. (Epub. Ahead of print)

Dubé N, Bourdeau A, Heinonen KM, Cheng A, Loy AL, Tremblay ML. 2005. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res. 65: 10088-10095.

Dubé N, Cheng A, Tremblay ML. 2004. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. U.S.A. 101: 1834-1839.

Dubé N, Tremblay ML. 2005. Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim. Biophys. Acta. 1754: 108-117.

Fackenthal JD, Olopade OI. 2007. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer. 7: 937-948.

Freiss G, Vignon F. 1994. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol. Endocrinol. 8: 1389-1396.

Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS; ABREAST Investigators. 2005. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer 5: 391-401.

Hsiao WC, Young KC, Lin SL, Lin PW. 2004. Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res. 6: R180-R186.

Hsu JL, Glaser SL, West DW. 1997. Racial/ethnic differences in breast cancer survival among San Francisco Bay Area women. J. Natl. Cancer Inst. 89: 1311-1312.

Huebner K, Croce CM. 2001. FRA3B and other common fragile sites: the weakest links. Nat. Rev. Cancer 1: 214-221.

Hunter T. 2000. Signaling-2000 and beyond. Cell 100: 113-127.

Iuliano R, Trapasso F, Le Pera I, Schepis F, Samà I, Clodomiro A, Dumon KR, Santoro M, Chiariotti L, Viglietto G, Fusco A. 2003. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. 63: 882-886.

Jayasinghe UW, Bilous AM, Boyages J. 2007. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J. 13: 479-485.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57: 43-66.

Jordan VC, O’Malley BW. 2007. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25: 5815-5824.

Julien SG, Dubé N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML. 2007. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39: 338-346.

Kaplan R, Morse B, Huebner K, Croce C, Howk R, Ravera M, Ricca G, Jaye M, Schlessinger J. 1990. Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. Proc. Natl. Acad. Sci. U.S.A. 87: 7000-7004.

Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S. 1996. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 56: 4236-4243.

Kidd KR, Kerns BJ, Dodge RK, Wiener JR. 1992. Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators. J. Histochem. Cytochem. 40: 729-735.

Krueger NX, Saito H. 1992. A human transmembrane protein-tyrosine-phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc. Natl. Acad. Sci. U.S.A. 89: 7417-7421.

Kulp SK, Liu S, Sugimoto Y, Brueggemeier RW, Lin YC. 2000. Localization of protein tyrosine phosphatase γ (RPTPγ) to the mammary epithelium of ACI rats. Biol. Reprod. 62: 181-182.

LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Boghosian-Sell L, Glick J, Weston A. 1991. Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc. Natl. Acad. Sci. U.S.A. 88: 5036-5040.

LaForgia S, Lasota J, Latif F, Boghosian-Sell L, Kastury K, Ohta M, Druck T, Atchison L, Cannizzaro LA, Barnea G. 1993. Detailed genetic and physical map of the 3p chromosome region surrounding the familial renal cell carcinoma chromosome translocation, t(3;8)(p14.2;q24.1). Cancer Res. 53: 3118-3124.

Lamprianou S, Vacaresse N, Suzuki Y, Meziane H, Buxbaum JD, Schlessinger J, Harroch S. 2006. Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development. Mol. Cell Biol. 26: 5106-5119.

Lee JH, Yim SH, Won YJ, Jung KW, Son BH, Lee HD, Lee ES, Yoo KY, Ahn SH, Shin HR; Members of Korean Breast Cancer Society (KBCS). 2007. Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J. Korean Med. Sci. Suppl.: S11-S16.

Lee SC, Hou MF, Hsieh PC, Wu SH, Ann Hou L, Ma H, Tsai SM, Tsai LY. 2008. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin. Biochem. 41: 121-125.

Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang JT, Cannizzaro LA, Park SH, Druck T. 1993. The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J. Biol. Chem. 268: 10573-10581.

Lim KL, Kolatkar PR, Ng KP, Ng CH, Pallen CJ. 1998. Interconversion of the kinetic identities of the tandem catalytic domains of receptor-like protein-tyrosine phosphatase PTPalpha by two point mutations is synergistic and substrate-dependent. J. Biol. Chem. 273: 28986-28993.

Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. 2001. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3: 802-808.

Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL, Lin YC. 2002a. Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents. Breast Cancer Res. Treat. 71: 21-35.

Liu S, Sugimoto Y, Kulp SK, Jiang J, Chang HL, Park KY, Kashida Y, Lin YC. 2002b. Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Res. 22: 3917-3923.

Liu S, Sugimoto Y, Sorio C, Tecchio C, Lin YC. 2004. Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. Oncogene 23: 1256-1262.

Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, McCue P, Druck T, Huebner K. 1994. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res. 54: 3710-3713.

Ma H, Bernstein L, Ross RK, Ursin G. 2006. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res. 8: R39.

Meng K, Rodriguez-Peña A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. 2000. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. U.S.A. 97: 2603-2608.

Mettlin C. 1999. Global breast cancer mortality statistics. CA Cancer J. Clin. 49: 138-144.

Montagner A, Yart A, Dance M, Perret B, Salles JP, Raynal P. 2005. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280: 5350-5360.

Morrison AS, Lowe CR, MacMahon B, Ravnihar B, Yuasa S. 1976. Some international differences in treatment and survival in breast cancer. Int. J. Cancer. 18: 269-273.

Nam HJ, Poy F, Saito H, Frederick CA. 2005. Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J. Exp. Med. 201: 441-452.

Natarajan N, Nemoto D, Nemoto T, Mettlin C. 1988. Breast cancer survival among Orientals and whites living in the United States. J. Surg. Oncol. 39: 206-209.

Nishikura K. 2006. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat. Rev. Mol. Cell Biol. 7: 919-931.

Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F ; NCI-Naple Breast Cancer Group. 2005. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12: 721-747.

Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T. 2002. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62: 6390-6394.

Osborne C, Wilson P, Tripathy D. 2004. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9: 361-377.

Osborne CK, Schiff R. 2005. Aromatase inhibitors: future directions. J. Steroid Biochem. Mol. Biol. 95: 183-187.

Ostman A, Hellberg C, Böhmer FD. 2006. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6: 307-320.

Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. 1992. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 52: 4773-4778.

Ottenhoff-Kalff AE, van Oirschot BA, Hennipman A, de Weger RA, Staal GE, Rijksen G. 1995. Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer. Breast Cancer Res. Treat. 33: 245-256.

Panagopoulos I, Pandis N, Thelin S, Petersson C, Mertens F, Borg A, Kristoffersson U, Mitelman F, Aman P. 1996. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56: 4871-4875.

Pariser H, Perez-Pinera P, Ezquerra L, Herradon G, Deuel TF. 2005. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. Biochem. Biophys. Res. Commun. 335: 232-239.

Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.

Rebecca S, Carol B. 2000. Concepts in oncology therapeutics, second edition: 2-18.

Ring A, Dowsett M. 2004. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11: 643-658.

Sawyers C. 2004. Targeted cancer therapy. Nature 432: 294-297.

Schumann G, Fiebich BL, Menzel D, Hüll M, Butcher R, Nielsen P, Bauer J. 1998. Cytokine-induced transcription of protein-tyrosine-phosphatases in human astrocytoma cells. Brain. Res. Mol. Brain Res. 62 : 56-64.

Shintani T, Maeda N, Nishiwaki T, Noda M. 1997. Characterization of rat receptor-like protein tyrosine phosphatase gamma isoforms. Biochem. Biophys. Res. Commun. 230: 419-425.

Shintani T, Maeda N, Noda M. 2001. Receptor-like protein tyrosine phosphatase gamma (RPTPgamma), but not PTPzeta/RPTPbeta, inhibits nerve-growth-factor-induced neurite outgrowth in PC12D cells. Dev. Neurosci. 23: 55-69.

Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. 1997. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 94: 13771-13776.

Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M. 2006. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J. Clin. 56: 168-183.

Sorio C, Mendrola J, Lou Z, LaForgia S, Croce CM, Huebner K. 1995. Characterization of the receptor protein tyrosine phosphatase gene product PTP gamma: binding and activation by triphosphorylated nucleosides. Cancer Res. 55: 4855-4864.

Sorio C, Melotti P, D’Arcangelo D, Mendrola J, Calabretta B, Croce CM, Huebner K. 1997. Receptor protein tyrosine phosphatase gamma, Ptp gamma, regulates hematopoietic differentiation. Blood 90: 49-57.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98: 10869-10874.

Stewart B and Kleihues P. 2003. Breast cancer. World cancer report. Lyon: IARC Press 188-199.

Tabiti K, Smith DR, Goh HS, Pallen CJ. 1995. Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas. Cancer Lett. 93: 239-248.

Tamura H, Fukada M, Fujikawa A, Noda M. 2006. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci. Lett. 399: 33-38.

Tian N, Wu X, Zhang Y, Jin Y. 2008. A-to-I editing sites are a genomically encoded G: implications for the evolutionary significance and identification of novel editing sites. RNA 14: 211-216.

Tiganis T, Bennett AM. 2007. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J. 402: 1-15.

Tonks NK, Diltz CD, Fischer EH. 1988. Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem. 263: 6722-6730.

Tonks NK, Diltz CD, Fischer EH. 1988. Characterization of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem. 263: 6731-6737.

Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7: 833-846.

Trapasso F, Yendamuri S, Dumon KR, Iuliano R, Cesari R, Feig B, Seto R, Infante L, Ishii H, Vecchione A, During MJ, Croce CM, Fusco A. 2004. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis 25: 2107-2114.

Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP. 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156.

Tsukamoto T, Takahashi T, Ueda R, Hibi K, Saito H, Takahashi T. 1992. Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines. Cancer Res. 52: 3506-3509.

Ueno M, Kiba T, Nishimura T, Kitano T, Yanagihara K, Yoshikawa K, Ishiguro H, Teramukai S, Fukushima M, Kato H, Inamoto T. 2007. Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital. Eur. J. Surg. Oncol. 33 : 696-699.

van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP. 2005. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J. Clin. Oncol. 23: 3886-3896.

van Niekerk CC, Poels LG. 1999. Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors. Cancer Lett. 137: 61-73.

Vezzalini M, Mombello A, Menestrina F, Mafficini A, Della Peruta M, van Niekerk C, Barbareschi M, Scarpa A, Sorio C. 2007. Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. Histopathology 50: 615-628.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304: 1164-1166.

Wary KK, Lou Z, Buchberg AM, Siracusa LD, Druck T, LaForgia S, Huebner K. 1993. A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells. Cancer Res. 53: 1498-1502.

Yang L, Parkin DM, Ferlay J, Li L, Chen Y. 2005. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev. 14: 243-250.

Yu SC, Lin PW, Liaw KY, Lin CC. 1985. Fine needle aspiration cytology of breast tumors. J. Formos. Med. Assoc. 84: 727-734.

Zheng J, Kulp SK, Zhang Y, Sugimoto Y, Dayton MA, Govindan MV, Brueggemeier RW, Lin YC. 2000. 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. Anticancer Res. 20: 11-19.

Zheng XM, Resnick RJ, Shalloway D. 2000. A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J. 19: 964-978.

Zheng XM, Wang Y, Pallen CJ. 1992. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 359: 336-339.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top